![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TUBGCP3 |
Gene summary for TUBGCP3 |
![]() |
Gene information | Species | Human | Gene symbol | TUBGCP3 | Gene ID | 10426 |
Gene name | tubulin gamma complex associated protein 3 | |
Gene Alias | 104p | |
Cytomap | 13q34 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B4DYP7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10426 | TUBGCP3 | C04 | Human | Oral cavity | OSCC | 1.99e-09 | 5.81e-01 | 0.2633 |
10426 | TUBGCP3 | C21 | Human | Oral cavity | OSCC | 3.31e-18 | 5.56e-01 | 0.2678 |
10426 | TUBGCP3 | C30 | Human | Oral cavity | OSCC | 2.61e-11 | 6.42e-01 | 0.3055 |
10426 | TUBGCP3 | C43 | Human | Oral cavity | OSCC | 1.08e-07 | 1.98e-01 | 0.1704 |
10426 | TUBGCP3 | C46 | Human | Oral cavity | OSCC | 3.07e-06 | 2.40e-01 | 0.1673 |
10426 | TUBGCP3 | C06 | Human | Oral cavity | OSCC | 1.21e-03 | 6.65e-01 | 0.2699 |
10426 | TUBGCP3 | C08 | Human | Oral cavity | OSCC | 3.28e-10 | 2.46e-01 | 0.1919 |
10426 | TUBGCP3 | EOLP-1 | Human | Oral cavity | EOLP | 1.87e-04 | 1.72e-01 | -0.0202 |
10426 | TUBGCP3 | SYSMH3 | Human | Oral cavity | OSCC | 5.78e-03 | 1.07e-01 | 0.2442 |
10426 | TUBGCP3 | SYSMH5 | Human | Oral cavity | OSCC | 4.43e-03 | 6.46e-02 | 0.0647 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070517 | Oral cavity | OSCC | spindle organization | 117/7305 | 184/18723 | 1.16e-11 | 4.17e-10 | 117 |
GO:005125820 | Oral cavity | OSCC | protein polymerization | 169/7305 | 297/18723 | 2.57e-10 | 7.17e-09 | 169 |
GO:00512255 | Oral cavity | OSCC | spindle assembly | 73/7305 | 117/18723 | 2.51e-07 | 3.96e-06 | 73 |
GO:00070204 | Oral cavity | OSCC | microtubule nucleation | 28/7305 | 35/18723 | 8.71e-07 | 1.19e-05 | 28 |
GO:00311226 | Oral cavity | OSCC | cytoplasmic microtubule organization | 39/7305 | 56/18723 | 3.29e-06 | 3.93e-05 | 39 |
GO:00467855 | Oral cavity | OSCC | microtubule polymerization | 53/7305 | 83/18723 | 3.96e-06 | 4.65e-05 | 53 |
GO:00311093 | Oral cavity | OSCC | microtubule polymerization or depolymerization | 68/7305 | 122/18723 | 1.29e-04 | 9.21e-04 | 68 |
GO:005125825 | Oral cavity | EOLP | protein polymerization | 74/2218 | 297/18723 | 2.65e-10 | 2.45e-08 | 74 |
GO:00070202 | Oral cavity | EOLP | microtubule nucleation | 14/2218 | 35/18723 | 2.11e-05 | 3.28e-04 | 14 |
GO:004678521 | Oral cavity | EOLP | microtubule polymerization | 23/2218 | 83/18723 | 6.67e-05 | 8.27e-04 | 23 |
GO:003112213 | Oral cavity | EOLP | cytoplasmic microtubule organization | 16/2218 | 56/18723 | 5.70e-04 | 4.82e-03 | 16 |
GO:00311091 | Oral cavity | EOLP | microtubule polymerization or depolymerization | 26/2218 | 122/18723 | 2.01e-03 | 1.28e-02 | 26 |
GO:000705121 | Oral cavity | EOLP | spindle organization | 35/2218 | 184/18723 | 3.05e-03 | 1.79e-02 | 35 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TUBGCP3 | SNV | Missense_Mutation | novel | c.860N>C | p.Leu287Ser | p.L287S | Q96CW5 | protein_coding | tolerated(0.44) | benign(0.18) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
TUBGCP3 | SNV | Missense_Mutation | c.2570T>C | p.Ile857Thr | p.I857T | Q96CW5 | protein_coding | tolerated(0.27) | benign(0.001) | TCGA-BR-8487-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TUBGCP3 | SNV | Missense_Mutation | c.2009N>T | p.Ala670Val | p.A670V | Q96CW5 | protein_coding | deleterious(0) | possibly_damaging(0.782) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
TUBGCP3 | SNV | Missense_Mutation | rs770585945 | c.437N>A | p.Arg146Gln | p.R146Q | Q96CW5 | protein_coding | tolerated(0.05) | benign(0.098) | TCGA-CD-8528-01 | Stomach | stomach adenocarcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR |
TUBGCP3 | SNV | Missense_Mutation | rs375434522 | c.313N>T | p.Arg105Cys | p.R105C | Q96CW5 | protein_coding | deleterious(0.01) | possibly_damaging(0.844) | TCGA-CG-4460-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PD |
TUBGCP3 | SNV | Missense_Mutation | c.2104C>T | p.His702Tyr | p.H702Y | Q96CW5 | protein_coding | deleterious(0) | possibly_damaging(0.766) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
TUBGCP3 | SNV | Missense_Mutation | c.2371G>A | p.Ala791Thr | p.A791T | Q96CW5 | protein_coding | tolerated(0.54) | benign(0) | TCGA-EQ-8122-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
TUBGCP3 | SNV | Missense_Mutation | novel | c.1819N>A | p.Ala607Thr | p.A607T | Q96CW5 | protein_coding | deleterious(0) | possibly_damaging(0.896) | TCGA-HF-A5NB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
TUBGCP3 | SNV | Missense_Mutation | c.1828N>A | p.Ala610Thr | p.A610T | Q96CW5 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | ||
TUBGCP3 | SNV | Missense_Mutation | rs777071272 | c.191N>A | p.Arg64Gln | p.R64Q | Q96CW5 | protein_coding | deleterious(0.01) | benign(0.084) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |